Line up to six companies across valuation, growth, profitability, leverage, ownership and technicals. Best and worst per row are highlighted.
| Metric | LALPATHLAB | VIJAYA | METROPOLIS | THYROCARE | NEPHROPLUS |
|---|---|---|---|---|---|
| Size & Price | |||||
| Market capitalisation | ₹33,605 Cr | ₹14,694 Cr | ₹11,151 Cr | ₹8,495 Cr | ₹6,509 Cr |
| Enterprise value | ₹33,605 Cr | ₹14,694 Cr | ₹11,169 Cr | ₹8,495 Cr | ₹6,589 Cr |
| Revenue (TTM) | ₹2,891 Cr | ₹857 Cr | ₹1,710 Cr | ₹876 Cr | ₹999 Cr |
| EBITDA (TTM) | ₹838 Cr | ₹362 Cr | ₹422 Cr | ₹282 Cr | ₹227 Cr |
| PAT (TTM) | ₹542 Cr | ₹187 Cr | ₹202 Cr | ₹176 Cr | ₹77 Cr |
| Current price | ₹2,005.10 | ₹1,428.00 | ₹537.90 | ₹533.60 | ₹648.95 |
| 1-day change | +0.91% | -0.67% | -0.7% | -0.1% | -1.64% |
| Avg volume (30d) | — | — | — | — | — |
| 52-week high | — | — | — | — | — |
| 52-week low | — | — | — | — | — |
| Distance from 52w high | — | — | — | — | — |
| Distance from 52w low | — | — | — | — | — |
| Valuation | |||||
| Price to earnings | 62.0× | 78.4× | 55.3× | 48.2× | 84.7× |
| Price to book | 13.4× | 15.4× | 7.4× | 14.5× | 5.8× |
| Price to sales | 11.6× | 17.1× | 6.5× | 9.7× | 6.5× |
| EV / EBITDA | 40.1× | 40.6× | 26.5× | 30.2× | 29.0× |
| Dividend yield | 1.27% | 0.14% | 0.93% | 6.56% | 0% |
| Earnings yield | 1.61% | 1.28% | 1.81% | 2.08% | 1.18% |
| PEG ratio | 2.19 | 2.91 | 5.55 | 1.33 | — |
| Book value / share | ₹149.7 | ₹93.0 | ₹73.0 | ₹36.8 | ₹111.3 |
| EPS (TTM) | ₹32.3 | ₹18.2 | ₹9.7 | ₹11.1 | ₹7.7 |
| Growth | |||||
| Sales growth (1y) | 12.2% | 19.5% | 23.6% | 20.6% | 32.2% |
| Sales growth (3y CAGR) | 11.1% | 21% | 12.8% | 16.3% | — |
| Sales growth (5y CAGR) | 11.8% | 16.7% | 10.5% | 10.9% | — |
| Profit growth (1y) | 3.6% | 20.9% | 31.1% | 78.2% | 14.5% |
| Profit growth (3y CAGR) | 28.3% | 26.9% | 10% | 36.2% | — |
| Profit growth (5y CAGR) | 11.6% | 15.2% | 0.7% | 7.6% | — |
| Qtr sales growth (YoY) | 19.1% | 22.8% | 16.6% | 24.3% | — |
| Qtr profit growth (YoY) | 27.2% | 37.6% | 25.7% | 34.1% | — |
| Profitability | |||||
| Operating margin | 28.3% | 41.4% | 24.4% | 31.6% | 22.7% |
| Net margin | 18.5% | 21.3% | 11.6% | 19.6% | 7.7% |
| Return on equity | 21.6% | 19.7% | 13.4% | 28.8% | 9.1% |
| Return on capital employed | 28.8% | 21.3% | 17.3% | 36.5% | 17.1% |
| Return on assets | 16.2% | 11.5% | 8.9% | 21.8% | 5.2% |
| ROE (3y avg) | 22% | 19.7% | 12.5% | 19.7% | 10.3% |
| ROCE (3y avg) | 28.8% | 21.7% | 15.8% | 27.1% | 16.1% |
| Leverage & Quality | |||||
| Debt to equity | 0 | 0 | 0.01 | 0 | 0.07 |
| Interest coverage | 31.7× | 8.0× | 11.9× | 78.7× | 2.7× |
| Current ratio | 3.48 | 2.6 | 1.4 | 3.39 | 2.8 |
| Working capital days | -79 | -117 | -57 | 4 | -61 |
| Ownership | |||||
| Promoter holding | 53.2% | 52.5% | 48.9% | 60.9% | 63.9% |
| Promoter pledge | 0% | 0% | 0% | 0% | 0% |
| FII holding | 17.4% | 11.7% | 11% | 5.4% | 8.8% |
| DII holding | 21.6% | 31.6% | 35.1% | 20.9% | 9.1% |
| Public holding | 7.5% | 4.2% | 5% | 12.7% | 18.3% |
| Promoter holding change (1y) | -0.6% | -0.12% | -0.03% | -10.14% | — |
| Technical | |||||
| 50-day moving average | — | — | — | — | — |
| 200-day moving average | — | — | — | — | — |
| Price vs 50 DMA | — | — | — | — | — |
| Price vs 200 DMA | — | — | — | — | — |
| RSI (14) | — | — | — | — | — |
| Return (1m) | — | — | — | — | — |
| Return (3m) | — | — | — | — | — |
| Return (6m) | — | — | — | — | — |
| Return (1y) | — | — | — | — | — |
| Return (3y CAGR) | — | — | — | — | — |
| Relative strength (1y) | — | — | — | — | — |
| Volatility (1y) | — | — | — | — | — |
| Beta | — | — | — | — | — |
best in row weakest in rowRows without a better/worse direction aren't highlighted.
| Line item | LALPATHLABMar 2020 · 2020-03-31Consolidated | VIJAYANo filing this year | METROPOLISMar 2020 · 2020-03-31Consolidated | THYROCAREMar 2020 · 2020-03-31Consolidated | NEPHROPLUSNo filing this year |
|---|---|---|---|---|---|
| Revenue | 1,330 | — | 856 | 433 | — |
| COGS | 299 | — | 204 | 117 | — |
| Gross profit | 1,032 | — | 652 | 316 | — |
| Operating expenses | 688 | — | 420 | 143 | — |
| Operating profit (EBITDA) | 344 | — | 232 | 173 | — |
| OPM % | 25.8% | — | 27.1% | 39.9% | — |
| Depreciation | 73 | — | 39 | 32 | — |
| Interest | 15 | — | 8 | 2 | — |
| Other income | 55 | — | -16 | 1 | — |
| Profit before tax | 311 | — | 169 | 140 | — |
| Tax | 83 | — | 41 | 52 | — |
| Tax % | 26.7% | — | 24.4% | 37% | — |
| PAT | 228 | — | 128 | 88 | — |
| PAT margin % | 17.1% | — | 14.9% | 20.4% | — |
| EPS (₹) | 27.4 | — | 25.4 | 16.7 | — |
A blank means that line was not filed or cannot be derived for that company. Compare periods and basis labels before reading across a row.